SlideShare una empresa de Scribd logo
1 de 8
Descargar para leer sin conexión
Regina LaBelle, Chief of Staff
Office of National Drug Control Policy
April 23, 2014
Vision Session
National RX Drug Abuse Summit
0
5
10
15
20
25
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
Deathsper100,000population
Motor Vehicle Traffic Poisoning Drug Poisoning (Overdose)
Source: NCHS Data Brief, December, 2011, Updated with 2009 and 2010 mortality data
U.S. Death Rate Trends, 1980-2010
Source of Prescription Pain Relievers
Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2009-2010
•  Coordinated effort across
the Federal Government
•  Four focus areas:
1)  Education
2)  Prescription Drug
Monitoring Programs
3)  Proper Disposal of
Medication
4)  Enforcement
Prescription Drug Abuse
Prevention Plan
Source: PDMP Training and Technical Assistance Center, Brandeis University, 2013
Prescription Drug Monitoring Programs
How to Recognize and Respond
to an Opioid Overdose
•  The American Society of Anesthesiologists (ASA) has
created a card explaining how to recognize and respond
to an opioid overdose.
•  The card, called “Opioid Overdose Resuscitation,” is
available for download on the ASA Web site.
•  To download the card, go to: http://www.asahq.org/
WhenSecondsCount/resources
•  There are signs that efforts to reduce and prevent prescription drug
abuse are working.
o  National data show the rate of past-month nonmedical use of prescription
medicines among young adults aged 18 to 25 over the past two years is lower
than the rate from 2003 - 2010.1
•  State public health and public safety professionals can take steps to
promote safer prescribing practices; improved prescription monitoring;
safe disposal; and effective monitoring, intervention, treatment and
overdose prevention.
•  Long-term success will come from coordination and collaboration at the
Federal, state, local, and tribal levels, particularly among public health and
public safety leaders.
Conclusion
1 Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National
Findings. U.S. Department of Health and Human Services. [September 2013]. Available: http://www.samhsa.gov/data/NSDUH/
2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm
For More Information:
WHITEHOUSE.GOV/ONDCP

Más contenido relacionado

La actualidad más candente

TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse Data
TRAINING 2  Unpacking Tennessee Adolescent Substance Misuse DataTRAINING 2  Unpacking Tennessee Adolescent Substance Misuse Data
TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse DataKarenChenoaSergent
 
Statewide Narcotics Screening Project
Statewide Narcotics Screening ProjectStatewide Narcotics Screening Project
Statewide Narcotics Screening ProjectTrevor Rohm
 
Pres arm2011 jun11_long
Pres arm2011 jun11_longPres arm2011 jun11_long
Pres arm2011 jun11_longsoder145
 
Partnering with Communities in Survey Design, Implementation and Dissemination
Partnering with Communities in Survey Design, Implementation and DisseminationPartnering with Communities in Survey Design, Implementation and Dissemination
Partnering with Communities in Survey Design, Implementation and Disseminationsoder145
 
The economic burden of prescription opioid overdose... 2013.
The economic burden of prescription opioid overdose... 2013.The economic burden of prescription opioid overdose... 2013.
The economic burden of prescription opioid overdose... 2013.Paul Coelho, MD
 
Green pt1 state-pmp
Green pt1 state-pmpGreen pt1 state-pmp
Green pt1 state-pmpWelcome40
 
Minnesota’s accountable communities for health
Minnesota’s accountable communities for health Minnesota’s accountable communities for health
Minnesota’s accountable communities for health soder145
 
Sample Frame Assessment for a Large Metropolitan County's Health Survey
Sample Frame Assessment for a Large Metropolitan County's Health SurveySample Frame Assessment for a Large Metropolitan County's Health Survey
Sample Frame Assessment for a Large Metropolitan County's Health Surveysoder145
 
Overview of the MNHA survey, methodology, and evidence of the impact of the a...
Overview of the MNHA survey, methodology, and evidence of the impact of the a...Overview of the MNHA survey, methodology, and evidence of the impact of the a...
Overview of the MNHA survey, methodology, and evidence of the impact of the a...soder145
 
Politico Pro Health Care Briefing: Drug Safety and the Trump FDA
Politico Pro Health Care Briefing: Drug Safety and the Trump FDAPolitico Pro Health Care Briefing: Drug Safety and the Trump FDA
Politico Pro Health Care Briefing: Drug Safety and the Trump FDACVS Health
 
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...soder145
 
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalWed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalOPUNITE
 
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Canadian Organization for Rare Disorders
 
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionSummer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionCanadian Organization for Rare Disorders
 
Addressing Rising Health Care Costs | CVS Health
Addressing Rising Health Care Costs | CVS HealthAddressing Rising Health Care Costs | CVS Health
Addressing Rising Health Care Costs | CVS HealthCVS Health
 
Challenges of pharmaceutical industry in 2015
Challenges of pharmaceutical industry in 2015Challenges of pharmaceutical industry in 2015
Challenges of pharmaceutical industry in 2015yahyasultan
 
Changing Trends in Employer Sponsored Insurance After the Affordable Care Act
Changing Trends in Employer Sponsored Insurance After the Affordable Care ActChanging Trends in Employer Sponsored Insurance After the Affordable Care Act
Changing Trends in Employer Sponsored Insurance After the Affordable Care Actsoder145
 

La actualidad más candente (20)

TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse Data
TRAINING 2  Unpacking Tennessee Adolescent Substance Misuse DataTRAINING 2  Unpacking Tennessee Adolescent Substance Misuse Data
TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse Data
 
Statewide Narcotics Screening Project
Statewide Narcotics Screening ProjectStatewide Narcotics Screening Project
Statewide Narcotics Screening Project
 
Webinar 3: Bringing Home the 5% Solution
Webinar 3: Bringing Home the 5% SolutionWebinar 3: Bringing Home the 5% Solution
Webinar 3: Bringing Home the 5% Solution
 
Pres arm2011 jun11_long
Pres arm2011 jun11_longPres arm2011 jun11_long
Pres arm2011 jun11_long
 
Partnering with Communities in Survey Design, Implementation and Dissemination
Partnering with Communities in Survey Design, Implementation and DisseminationPartnering with Communities in Survey Design, Implementation and Dissemination
Partnering with Communities in Survey Design, Implementation and Dissemination
 
The economic burden of prescription opioid overdose... 2013.
The economic burden of prescription opioid overdose... 2013.The economic burden of prescription opioid overdose... 2013.
The economic burden of prescription opioid overdose... 2013.
 
Green pt1 state-pmp
Green pt1 state-pmpGreen pt1 state-pmp
Green pt1 state-pmp
 
Minnesota’s accountable communities for health
Minnesota’s accountable communities for health Minnesota’s accountable communities for health
Minnesota’s accountable communities for health
 
Sample Frame Assessment for a Large Metropolitan County's Health Survey
Sample Frame Assessment for a Large Metropolitan County's Health SurveySample Frame Assessment for a Large Metropolitan County's Health Survey
Sample Frame Assessment for a Large Metropolitan County's Health Survey
 
Overview of the MNHA survey, methodology, and evidence of the impact of the a...
Overview of the MNHA survey, methodology, and evidence of the impact of the a...Overview of the MNHA survey, methodology, and evidence of the impact of the a...
Overview of the MNHA survey, methodology, and evidence of the impact of the a...
 
Politico Pro Health Care Briefing: Drug Safety and the Trump FDA
Politico Pro Health Care Briefing: Drug Safety and the Trump FDAPolitico Pro Health Care Briefing: Drug Safety and the Trump FDA
Politico Pro Health Care Briefing: Drug Safety and the Trump FDA
 
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...
Location, Location, Location: Leveraging Interactive Maps and ZIP Code Level ...
 
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalWed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
 
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
 
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
 
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
 
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionSummer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
 
Addressing Rising Health Care Costs | CVS Health
Addressing Rising Health Care Costs | CVS HealthAddressing Rising Health Care Costs | CVS Health
Addressing Rising Health Care Costs | CVS Health
 
Challenges of pharmaceutical industry in 2015
Challenges of pharmaceutical industry in 2015Challenges of pharmaceutical industry in 2015
Challenges of pharmaceutical industry in 2015
 
Changing Trends in Employer Sponsored Insurance After the Affordable Care Act
Changing Trends in Employer Sponsored Insurance After the Affordable Care ActChanging Trends in Employer Sponsored Insurance After the Affordable Care Act
Changing Trends in Employer Sponsored Insurance After the Affordable Care Act
 

Similar a Wed vs ondcp labelle

Tuesday astho
Tuesday asthoTuesday astho
Tuesday asthoOPUNITE
 
State profile -_new_york_0
State profile -_new_york_0State profile -_new_york_0
State profile -_new_york_0satoriwatersfl
 
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazon
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazonRx15 tt tues_1230_1_carnevale_2green_3paone-tuazon
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazonOPUNITE
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchOPUNITE
 
Intro to Prevention: Psychopharmacology Guest Lecture
Intro to Prevention: Psychopharmacology Guest LectureIntro to Prevention: Psychopharmacology Guest Lecture
Intro to Prevention: Psychopharmacology Guest LectureJulie Hynes
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.pptShirazKhokhar1
 
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINALLeah Ramirez
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Drug abuse a public health concern
Drug abuse a  public health concernDrug abuse a  public health concern
Drug abuse a public health concernIshtiaque Khan
 
State profile -_florida
State profile -_floridaState profile -_florida
State profile -_floridasatoriwatersfl
 
Drugs & alcohol scoping workshop 3-6-15 final
Drugs & alcohol scoping workshop  3-6-15 finalDrugs & alcohol scoping workshop  3-6-15 final
Drugs & alcohol scoping workshop 3-6-15 finalCambridgeshireInsight
 
Global Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
Global Medical Cures™ | Responding to America's Prescription Drug Abuse CrisisGlobal Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
Global Medical Cures™ | Responding to America's Prescription Drug Abuse CrisisGlobal Medical Cures™
 
Ea 4 cline raduka_wood
Ea 4 cline raduka_woodEa 4 cline raduka_wood
Ea 4 cline raduka_woodOPUNITE
 
Tue vs ondcp spitznas
Tue vs   ondcp spitznasTue vs   ondcp spitznas
Tue vs ondcp spitznasOPUNITE
 
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwardsRx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwardsOPUNITE
 
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberry
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberryRx15 pdmp tues_330_1_brown_2fondario_3quesinberry
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberryOPUNITE
 
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...Ardhany Rc
 
Maldives National drug use survey 2012
Maldives National drug use survey 2012Maldives National drug use survey 2012
Maldives National drug use survey 2012Achmed Adam
 

Similar a Wed vs ondcp labelle (20)

Tuesday astho
Tuesday asthoTuesday astho
Tuesday astho
 
State profile -_new_york_0
State profile -_new_york_0State profile -_new_york_0
State profile -_new_york_0
 
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazon
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazonRx15 tt tues_1230_1_carnevale_2green_3paone-tuazon
Rx15 tt tues_1230_1_carnevale_2green_3paone-tuazon
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
 
Intro to Prevention: Psychopharmacology Guest Lecture
Intro to Prevention: Psychopharmacology Guest LectureIntro to Prevention: Psychopharmacology Guest Lecture
Intro to Prevention: Psychopharmacology Guest Lecture
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt
 
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL
150929 Prevention of Opioid Pain Reliever Misuse in Arkansas FINAL
 
CR_drug_abuse_2016
CR_drug_abuse_2016CR_drug_abuse_2016
CR_drug_abuse_2016
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Drug abuse a public health concern
Drug abuse a  public health concernDrug abuse a  public health concern
Drug abuse a public health concern
 
State profile -_florida
State profile -_floridaState profile -_florida
State profile -_florida
 
Drugs & alcohol scoping workshop 3-6-15 final
Drugs & alcohol scoping workshop  3-6-15 finalDrugs & alcohol scoping workshop  3-6-15 final
Drugs & alcohol scoping workshop 3-6-15 final
 
Global Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
Global Medical Cures™ | Responding to America's Prescription Drug Abuse CrisisGlobal Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
Global Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
 
Ea 4 cline raduka_wood
Ea 4 cline raduka_woodEa 4 cline raduka_wood
Ea 4 cline raduka_wood
 
Tue vs ondcp spitznas
Tue vs   ondcp spitznasTue vs   ondcp spitznas
Tue vs ondcp spitznas
 
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwardsRx15 ea tues_330_1_lovedale_2holton_3varney-edwards
Rx15 ea tues_330_1_lovedale_2holton_3varney-edwards
 
PRC Region 8 Regional Needs Assessment Overview
PRC Region 8 Regional Needs Assessment OverviewPRC Region 8 Regional Needs Assessment Overview
PRC Region 8 Regional Needs Assessment Overview
 
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberry
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberryRx15 pdmp tues_330_1_brown_2fondario_3quesinberry
Rx15 pdmp tues_330_1_brown_2fondario_3quesinberry
 
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...
IMPACT OF REHABILITATION RIGHT’S NEGLIGENCE FOR PEOPLE WHO USE DRUGS DURING T...
 
Maldives National drug use survey 2012
Maldives National drug use survey 2012Maldives National drug use survey 2012
Maldives National drug use survey 2012
 

Más de OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldOPUNITE
 

Más de OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 

Último

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthGokuldas Hospital
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)MedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 

Último (20)

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 

Wed vs ondcp labelle

  • 1. Regina LaBelle, Chief of Staff Office of National Drug Control Policy April 23, 2014 Vision Session National RX Drug Abuse Summit
  • 2. 0 5 10 15 20 25 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 Deathsper100,000population Motor Vehicle Traffic Poisoning Drug Poisoning (Overdose) Source: NCHS Data Brief, December, 2011, Updated with 2009 and 2010 mortality data U.S. Death Rate Trends, 1980-2010
  • 3. Source of Prescription Pain Relievers Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2009-2010
  • 4. •  Coordinated effort across the Federal Government •  Four focus areas: 1)  Education 2)  Prescription Drug Monitoring Programs 3)  Proper Disposal of Medication 4)  Enforcement Prescription Drug Abuse Prevention Plan
  • 5. Source: PDMP Training and Technical Assistance Center, Brandeis University, 2013 Prescription Drug Monitoring Programs
  • 6. How to Recognize and Respond to an Opioid Overdose •  The American Society of Anesthesiologists (ASA) has created a card explaining how to recognize and respond to an opioid overdose. •  The card, called “Opioid Overdose Resuscitation,” is available for download on the ASA Web site. •  To download the card, go to: http://www.asahq.org/ WhenSecondsCount/resources
  • 7. •  There are signs that efforts to reduce and prevent prescription drug abuse are working. o  National data show the rate of past-month nonmedical use of prescription medicines among young adults aged 18 to 25 over the past two years is lower than the rate from 2003 - 2010.1 •  State public health and public safety professionals can take steps to promote safer prescribing practices; improved prescription monitoring; safe disposal; and effective monitoring, intervention, treatment and overdose prevention. •  Long-term success will come from coordination and collaboration at the Federal, state, local, and tribal levels, particularly among public health and public safety leaders. Conclusion 1 Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. U.S. Department of Health and Human Services. [September 2013]. Available: http://www.samhsa.gov/data/NSDUH/ 2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm